AU757698C - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof - Google Patents

Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Info

Publication number
AU757698C
AU757698C AU43262/99A AU4326299A AU757698C AU 757698 C AU757698 C AU 757698C AU 43262/99 A AU43262/99 A AU 43262/99A AU 4326299 A AU4326299 A AU 4326299A AU 757698 C AU757698 C AU 757698C
Authority
AU
Australia
Prior art keywords
strap
protein
antibody
polynucleotide
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU43262/99A
Other languages
English (en)
Other versions
AU4326299A (en
AU757698B2 (en
Inventor
Daniel E. Afar
Rene S. Hubert
Kahan Leong
Stephen Chappell Mitchell
Arthur B. Raitano
Douglas C. Saffran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of AU4326299A publication Critical patent/AU4326299A/en
Assigned to AGENSYS, INC. reassignment AGENSYS, INC. Amend patent request/document other than specification (104) Assignors: UROGENESYS, INC.
Application granted granted Critical
Publication of AU757698B2 publication Critical patent/AU757698B2/en
Priority to AU2003204605A priority Critical patent/AU2003204605B2/en
Publication of AU757698C publication Critical patent/AU757698C/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
AU43262/99A 1998-06-01 1999-06-01 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof Expired AU757698C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003204605A AU2003204605B2 (en) 1998-06-01 2003-06-10 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8752098P 1998-06-01 1998-06-01
US60/087520 1998-06-01
US9118398P 1998-06-30 1998-06-30
US60/091183 1998-06-30
PCT/US1999/012157 WO1999062941A2 (en) 1998-06-01 1999-06-01 Serpentine transmembrane antigens expressed in human cancers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003204605A Division AU2003204605B2 (en) 1998-06-01 2003-06-10 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Publications (3)

Publication Number Publication Date
AU4326299A AU4326299A (en) 1999-12-20
AU757698B2 AU757698B2 (en) 2003-03-06
AU757698C true AU757698C (en) 2004-04-08

Family

ID=26777066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43262/99A Expired AU757698C (en) 1998-06-01 1999-06-01 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Country Status (13)

Country Link
US (10) US6329503B1 (enExample)
EP (2) EP2080802B1 (enExample)
JP (5) JP4855577B2 (enExample)
AT (1) ATE437947T1 (enExample)
AU (1) AU757698C (enExample)
CA (1) CA2328989C (enExample)
CY (1) CY1109509T1 (enExample)
DE (1) DE69941187D1 (enExample)
DK (1) DK1086223T3 (enExample)
ES (2) ES2629442T3 (enExample)
IL (2) IL139699A0 (enExample)
PT (1) PT1086223E (enExample)
WO (1) WO1999062941A2 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20020187472A1 (en) * 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
ES2629442T3 (es) * 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
US20030149531A1 (en) * 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040048798A1 (en) * 1999-06-01 2004-03-11 Raitano Arthur B. Nucleic acid and corresponding protein entitle 98P4B6 useful in treatment and detection of cancer
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU5416700A (en) * 1999-05-20 2000-12-12 Fahri Saatcioglu Differentially expressed genes in prostate cancer
US20060073150A1 (en) * 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
JP4827357B2 (ja) * 1999-12-06 2011-11-30 アジェンシス，インコーポレイテッド ヒト前立腺癌において発現されるヘビ状膜貫通抗原およびその使用方法
EP2338515A3 (en) * 2000-02-10 2011-11-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7189565B2 (en) * 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
AU4941101A (en) * 2000-03-24 2001-10-08 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
CN100497385C (zh) 2001-01-17 2009-06-10 因特里特控股有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
US20030194798A1 (en) 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7133725B2 (en) * 2001-12-19 2006-11-07 Wilk Patent Development Corporation Method and related composition employing nanostructures
WO2003072014A2 (en) 2002-02-25 2003-09-04 Mpex Bioscience, Inc. Minicell compositions and methods
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP5840351B2 (ja) * 2002-09-06 2016-01-06 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質
CN103394083B (zh) 2003-11-06 2017-07-18 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
BRPI0418766B8 (pt) 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
JP2009516757A (ja) * 2005-10-21 2009-04-23 メディバス エルエルシー ポリ（エステルウレア）ポリマーおよび使用法
WO2007109321A2 (en) 2006-03-20 2007-09-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
EP2082032A4 (en) * 2006-10-10 2010-06-30 Biosceptre Int Ltd ANTIBODIES AGAINST NON-FUNCTIONAL P2X7 RECEPTOR PRODUCING HYBRIDOMES
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
EP3838298B1 (en) 2007-08-17 2025-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
NZ583894A (en) 2007-09-14 2013-01-25 Biosceptre Int Ltd Antibodies that bind to a non atp binding p2x7 receptor
AU2008299594B2 (en) 2007-09-14 2013-10-03 Biosceptre International Limited Purinergic (P2X) receptors in extra-cellular body fluid
CA2700410C (en) * 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
WO2010000041A1 (en) 2008-07-04 2010-01-07 Biosceptre International Limiited Anti- p2x7 peptides and epitopes
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
ES2557456T3 (es) 2009-08-20 2016-01-26 Biosceptre (Aust) Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
ES2732021T3 (es) 2009-12-24 2019-11-20 Biosceptre Aust Pty Ltd Anticuerpos de receptores P2X7 oligoméricos no funcionales
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
NZ602840A (en) 2010-06-03 2014-11-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
WO2012031333A1 (en) 2010-09-10 2012-03-15 Biosceptre International Limited Companion animal treatments
WO2012057765A1 (en) 2010-10-28 2012-05-03 The Board Of Regents Of The University Of Texas System Recombinant anti-cd19 monoclonal antibodies
KR101939150B1 (ko) * 2010-11-12 2019-01-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도
AU2015261742B2 (en) * 2010-11-12 2017-10-26 Inovio Pharmaceuticals, Inc. Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
CA2827443C (en) 2011-02-15 2021-07-06 Vaxiion Therapeutics, Inc. Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
ES2689272T3 (es) 2011-07-01 2018-11-13 Biosceptre (Aust) Pty Ltd Terapia de combinación
US20130143237A1 (en) 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
EA201890915A1 (ru) 2012-11-15 2018-09-28 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
KR101782623B1 (ko) 2013-07-10 2017-09-28 서울대학교산학협력단 복합 막횡단 단백질의 세포막외 펩타이드 항원 및 그의 용도
HRP20240398T1 (hr) 2013-10-18 2024-06-07 Novartis Ag Označeni inhibitori prostata specifičnog membranskog antigena (psma), njihova upotreba kao sredstava za snimanje i farmaceutska sredstva za liječenje raka prostate
KR102457827B1 (ko) 2013-11-14 2022-10-24 엔도사이트, 인코포레이티드 양전자 방출 단층 촬영용 화합물
CA2979671C (en) 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
JP2018524295A (ja) 2015-06-15 2018-08-30 ジェネンテック， インコーポレイテッド 抗体及び免疫複合体
RU2765242C2 (ru) 2015-08-07 2022-01-27 Имаджинаб, Инк. Антигенсвязывающие конструкции против молекул-мишеней
CN109152811A (zh) 2015-12-18 2019-01-04 阿吉尔瓦克斯公司 与xCT肽相关的组合物和方法
WO2018058001A1 (en) * 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2018184966A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
CN111194222A (zh) 2017-05-01 2020-05-22 阿吉尔瓦克斯公司 与xCT抗体相关的组合物和方法
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
US12252544B2 (en) 2018-05-17 2025-03-18 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
UY38289A (es) 2018-07-02 2020-01-31 Amgen Inc Proteína de unión al antígeno anti-steap1
US20210277148A1 (en) * 2018-07-18 2021-09-09 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7592998A (en) * 1997-05-23 1998-12-11 Biogen, Inc. Modulators of tissue regeneration

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5851764A (en) * 1990-10-25 1998-12-22 The Trustees Of Columbia University In The City Of New York Human prostate tumor inducing gene-1 and uses thereof
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara GENE SIGNATURE.
JP4295826B2 (ja) * 1996-03-25 2009-07-15 メダレックス，インコーポレーテッド 前立腺特異的膜抗原の細胞外ドメインに対して特異的なモノクローナル抗体
US5859045A (en) * 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
EP0974057B1 (en) * 1996-07-15 2005-09-21 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
WO1998016628A1 (en) 1996-10-15 1998-04-23 The Regents Of The University Of California Animal models of human prostate cancer progression
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
BR9807734A (pt) 1997-02-25 2000-10-31 Corixa Corp Composto para imunodiagnose de câncer de próstata e métodos para o uso dos memos
IL131560A0 (en) 1997-02-25 2001-01-28 Corixa Corp Compounds for immunotherapy of prostate cancer and methods for their use
JP2001512011A (ja) 1997-08-01 2001-08-21 ジェンセット 組織非特異的分泌タンパク質の５’ｅｓｔ
CA2296287A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in prostate
JPH11164691A (ja) 1997-10-03 1999-06-22 Rikagaku Kenkyusho 胚盤胞ｃＤＮＡ
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6255049B1 (en) * 1998-02-27 2001-07-03 The Trustees Of Columbia University In The City Of New York Detection of metastatic cancer cells using PCTA-1
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
ES2629442T3 (es) * 1998-06-01 2017-08-09 Agensys, Inc. Nuevos antígenos transmembranales en serpentina expresados en cánceres humanos y utilizaciones de los mismos
TW200728465A (en) 1998-07-14 2007-08-01 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer
EP1140970A4 (en) 1998-12-17 2003-10-22 Human Genome Sciences Inc 47 HUMAN SECRETED PROTEINS
US6416758B1 (en) * 1999-04-28 2002-07-09 Board Of Regents, The University Of Texax System Antibody conjugate kits for selectively inhibiting VEGF
US20060073150A1 (en) 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
JP2003502061A (ja) 1999-06-11 2003-01-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４８個のヒト分泌タンパク質
JP2003527089A (ja) 1999-08-17 2003-09-16 インサイト・ゲノミックス・インコーポレイテッド 膜関連タンパク質
GB2354821A (en) 1999-09-29 2001-04-04 Dine O Quick Threshold crossing counter
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2391369A1 (en) 1999-11-12 2001-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP4827357B2 (ja) 1999-12-06 2011-11-30 アジェンシス，インコーポレイテッド ヒト前立腺癌において発現されるヘビ状膜貫通抗原およびその使用方法
RU2002121771A (ru) 2000-01-14 2004-03-10 Корикса Корпорейшн (Us) Композиции и способы для терапии и диагностики рака предстательной железы
WO2001057190A2 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001057252A2 (en) 2000-02-04 2001-08-09 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU4941101A (en) 2000-03-24 2001-10-08 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
JP2004504808A (ja) 2000-03-27 2004-02-19 コリクサ　コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
JP2004509612A (ja) 2000-06-05 2004-04-02 アバロン　ファーマシューティカルズ ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング
JP2004512022A (ja) 2000-06-09 2004-04-22 コリクサ　コーポレイション 結腸癌の治療および診断のための組成物および方法
EP1305450A2 (en) 2000-07-28 2003-05-02 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
KR20030029847A (ko) 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
EP1474528A4 (en) 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS FOR DIAGNOSING PROSTATE CANCER, COMPOSITIONS AND METHODS FOR SCREENING PROSTATE CANCER MODULATORS
EP1661986A1 (en) 2000-11-17 2006-05-31 Nuvelo, Inc. Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides
AU2002235871A1 (en) 2001-01-12 2002-07-30 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
CA2441755A1 (en) 2001-03-21 2003-05-08 Human Genome Sciences, Inc. Human secreted proteins
AU2002337657A1 (en) 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US6918525B2 (en) * 2003-05-23 2005-07-19 Worktools, Inc. Spring energized desktop stapler
BRPI0418766B8 (pt) 2004-04-22 2021-05-25 Agensys Inc anticorpo ou seu fragmento, vetor, composição farmacêutica, ensaio e método para detectar a presença de proteína steap-1, bem como método para distribuir um agente citotóxico ou um agente de diagnóstico
CN104447992A (zh) 2004-09-23 2015-03-25 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US7056186B1 (en) * 2005-04-06 2006-06-06 Weyenberg Karey M Cleavage-enhancing foundation garment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7592998A (en) * 1997-05-23 1998-12-11 Biogen, Inc. Modulators of tissue regeneration

Also Published As

Publication number Publication date
JP2012050434A (ja) 2012-03-15
WO1999062941A3 (en) 2000-04-06
JP2009106284A (ja) 2009-05-21
US20100190962A1 (en) 2010-07-29
US8414898B2 (en) 2013-04-09
JP6371362B2 (ja) 2018-08-08
CA2328989A1 (en) 1999-12-09
US7968307B2 (en) 2011-06-28
US7928201B2 (en) 2011-04-19
US20100173297A1 (en) 2010-07-08
WO1999062941A9 (en) 2000-09-14
US20110318371A1 (en) 2011-12-29
US20030045682A1 (en) 2003-03-06
EP1086223A2 (en) 2001-03-28
IL203524A (en) 2013-06-27
JP4871341B2 (ja) 2012-02-08
ES2629442T3 (es) 2017-08-09
US20030055217A1 (en) 2003-03-20
JP5683414B2 (ja) 2015-03-11
US20050064445A1 (en) 2005-03-24
JP2014239695A (ja) 2014-12-25
ATE437947T1 (de) 2009-08-15
US6329503B1 (en) 2001-12-11
US20060147951A1 (en) 2006-07-06
US7053186B2 (en) 2006-05-30
EP2080802A3 (en) 2009-08-05
US20050202454A1 (en) 2005-09-15
EP2080802B1 (en) 2017-03-29
US7611904B2 (en) 2009-11-03
CY1109509T1 (el) 2014-08-13
CA2328989C (en) 2012-02-07
US7166714B2 (en) 2007-01-23
IL139699A0 (en) 2002-02-10
WO1999062941A8 (en) 2000-08-03
EP2080802A2 (en) 2009-07-22
DE69941187D1 (de) 2009-09-10
JP2017079748A (ja) 2017-05-18
JP2002517184A (ja) 2002-06-18
WO1999062941A2 (en) 1999-12-09
AU4326299A (en) 1999-12-20
US6887975B2 (en) 2005-05-03
PT1086223E (pt) 2009-11-03
US20070104720A1 (en) 2007-05-10
US7642054B2 (en) 2010-01-05
US7575749B2 (en) 2009-08-18
ES2329851T3 (es) 2009-12-01
DK1086223T3 (da) 2009-11-30
EP1086223B1 (en) 2009-07-29
AU757698B2 (en) 2003-03-06
JP4855577B2 (ja) 2012-01-18

Similar Documents

Publication Publication Date Title
AU757698C (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US7455991B2 (en) Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU2003204605B2 (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
AU2006200459B2 (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
HK1133672A (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
HK1133672B (en) Novel serpentine transmembrane antigens expressed in human cancers and uses thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND TO UROGENESYS, INC

TC Change of applicant's name (sec. 104)

Owner name: AGENSYS, INC.

Free format text: FORMER NAME: UROGENESYS, INC.

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20030801

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20031009

MK14 Patent ceased section 143(a) (annual fees not paid) or expired